Literature DB >> 19387322

Predictors of survival after resection of early hepatocellular carcinoma.

Hari Nathan1, Richard D Schulick, Michael A Choti, Timothy M Pawlik.   

Abstract

OBJECTIVE: To identify clinicopathologic factors that predict survival following hepatectomy in patients with early hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: Although surgical resection of early HCC is thought to be associated with a good outcome, factors predictive of prognosis following resection of these tumors remain ill-defined.
METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients with histologically confirmed early HCC (< or =5 cm and no nodal involvement, metastases, or major vascular invasion) who underwent surgical resection (not ablation or transplantation) between 1988 and 2005. Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional hazards models.
RESULTS: The study included 788 patients. Median tumor size was 3.2 cm, and 20% of patients had tumors < or =2 cm. Most HCC lesions were solitary (74%) and had no evidence of vascular invasion (82%). Following surgery, overall median and 5-year survival were 45 months and 39%, respectively. After adjusting for demographic factors and histological grade, tumor size >2 cm (hazard ratio [HR]: 1.51), multifocal tumors (HR: 1.51), and vascular invasion (HR: 1.44) remained independent predictors of poor survival (all P < 0.05). Based on these findings, a prognostic scoring system was developed that allotted 1 point each for these factors. Patients with early HCC could be stratified into 3 distinct prognostic groups (median and 5-year survival, respectively): 0 points (70 months, 55%), 1 point (52 months, 42%), and > or =2 points (24 months, 29%) (P < 0.001).
CONCLUSIONS: Although early HCC is generally associated with a good prognosis, pathologic factors can still be used to stratify patients with respect to survival after resection. These data emphasize the importance of pathologic staging even in small HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19387322     DOI: 10.1097/SLA.0b013e3181a38eb5

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  91 in total

1.  MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.

Authors:  Zhaoqin Huang; Xiangjiao Meng; Jianjun Xiu; Xiuqin Xu; Lei Bi; Jie Zhang; Xue Han; Qingwei Liu
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Disparities in care for patients with curable hepatocellular carcinoma.

Authors:  Richard S Hoehn; Dennis J Hanseman; Peter L Jernigan; Koffi Wima; Audrey E Ertel; Daniel E Abbott; Shimul A Shah
Journal:  HPB (Oxford)       Date:  2015-09       Impact factor: 3.647

3.  Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.

Authors:  Kristina A Matkowskyj; Han Bai; Jie Liao; Wanying Zhang; Haonan Li; Sambasiva Rao; Reed Omary; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2013-12-18       Impact factor: 3.466

4.  Clinical outcome of hepatectomy for hepatocellular carcinomas≤2 cm.

Authors:  Tokihiko Sawada; Keiichi Kubota; Junji Kita; Masato Kato; Takayuki Shiraki; KyungHwa Park; Mitsugi Shimoda
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

5.  Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study.

Authors:  Wenjie Zhang; Kangpeng Jin; Fei Wang; Guangyan Zhangyuan; Weiwei Yu; Yang Liu; Haitian Zhang; Ping Zhang; Beicheng Sun
Journal:  United European Gastroenterol J       Date:  2019-04-24       Impact factor: 4.623

6.  Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma.

Authors:  Nader N Massarweh; James O Park; Farhood Farjah; Raymond S W Yeung; Rebecca Gaston Symons; Thomas L Vaughan; Laura-Mae Baldwin; David R Flum
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

7.  Histological grade of hepatocellular carcinoma predicted by quantitative diffusion-weighted imaging.

Authors:  Weihua Guo; Suhong Zhao; Yuhai Yang; Guangrui Shao
Journal:  Int J Clin Exp Med       Date:  2015-03-15

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.

Authors:  Jong Man Kim; Choon Hyuck; David Kwon; Jae-Won Joh; Joon Hyeok Lee; Seung Woon Paik; Cheol Keun Park
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

10.  Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

Authors:  Fadia T Shaya; Ian M Breunig; Brian Seal; C Daniel Mullins; Viktor V Chirikov; Nader Hanna
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.